BAO PHARMA-B (02659) has announced that on July 24, 2026, the company allocated approximately HK$1.9942 million to repurchase 115,200 of its own shares.
The buyback operation involved the expenditure of HK$1,994,200 to acquire 115,200 shares of the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments